-+ 0.00%
-+ 0.00%
-+ 0.00%

ASCLETIS PHARMA - TOPLINE PHASE III DATA EXPECTED Q3 2028; FDA NDA BY END 2028; EMA MAA EARLY 2029

Reuters·08/30/2026 10:15:03

Please log in to view news